Company Profile
TMS develops, manufactures, and sells drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment
TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development.
Additionally, it has a collaboration with Hokkaido University to evaluate the potential of the drug candidate compounds as novel drugs. Incorporated in 2005, TMS is headquartered in Fuchu, Japan.